{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Locally+Advanced+Unresectable+NSCLC&page=2",
    "query": {
      "condition": "Locally Advanced Unresectable NSCLC",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Locally+Advanced+Unresectable+NSCLC&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-24T20:41:10.676Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00003089",
      "title": "Chemotherapy, Amifostine, and Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Drug/Agent Toxicity by Tissue/Organ",
        "Lung Cancer"
      ],
      "interventions": [
        {
          "name": "amifostine trihydrate",
          "type": "DRUG"
        },
        {
          "name": "carboplatin",
          "type": "DRUG"
        },
        {
          "name": "paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "radiation therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "1997-07",
      "completion_date": "2004-02",
      "has_results": false,
      "last_update_posted_date": "2013-07-10",
      "last_synced_at": "2026-09-24T20:41:10.676Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00003089"
    },
    {
      "nct_id": "NCT06003231",
      "title": "A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Carcinoma, Non-Small-Cell Lung",
        "Ovarian Neoplasms",
        "Endometrial Neoplasms",
        "Head and Neck Neoplasms"
      ],
      "interventions": [
        {
          "name": "disitamab vedotin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Seagen, a wholly owned subsidiary of Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 120,
      "start_date": "2023-11-14",
      "completion_date": "2028-05-31",
      "has_results": false,
      "last_update_posted_date": "2026-07-22",
      "last_synced_at": "2026-09-24T20:41:10.676Z",
      "location_count": 75,
      "location_summary": "Chandler, Arizona • Gilbert, Arizona • Glendale, Arizona + 36 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06003231"
    },
    {
      "nct_id": "NCT04303780",
      "title": "Study to Compare AMG 510 \"Proposed INN Sotorasib\" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200).",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "KRAS p, G12c Mutated /Advanced Metastatic NSCLC"
      ],
      "interventions": [
        {
          "name": "AMG 510",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 345,
      "start_date": "2020-06-04",
      "completion_date": "2026-06-24",
      "has_results": true,
      "last_update_posted_date": "2026-07-22",
      "last_synced_at": "2026-09-24T20:41:10.676Z",
      "location_count": 54,
      "location_summary": "Anaheim, California • Duarte, California • Long Beach, California + 46 more",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04303780"
    },
    {
      "nct_id": "NCT02443324",
      "title": "A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Gastric Adenocarcinoma",
        "Adenocarcinoma of the Gastroesophageal Junction",
        "Non-small Cell Lung Cancer",
        "Carcinoma, Transitional Cell",
        "Biliary Tract Cancer"
      ],
      "interventions": [
        {
          "name": "Ramucirumab",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 175,
      "start_date": "2015-07-29",
      "completion_date": "2022-04-12",
      "has_results": true,
      "last_update_posted_date": "2024-07-31",
      "last_synced_at": "2026-09-24T20:41:10.676Z",
      "location_count": 7,
      "location_summary": "New Haven, Connecticut • Fort Myers, Florida • St. Petersburg, Florida + 3 more",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Fort Myers",
          "state": "Florida"
        },
        {
          "city": "St. Petersburg",
          "state": "Florida"
        },
        {
          "city": "Chattanooga",
          "state": "Tennessee"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02443324"
    },
    {
      "nct_id": "NCT05048797",
      "title": "A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Locally Advanced or Metastatic Non-Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Trastuzumab Deruxtecan",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Pemetrexed",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "123 Years",
        "sex": "ALL",
        "summary": "18 Years to 123 Years"
      },
      "enrollment_count": 454,
      "start_date": "2021-10-28",
      "completion_date": "2027-07-30",
      "has_results": false,
      "last_update_posted_date": "2026-07-10",
      "last_synced_at": "2026-09-24T20:41:10.676Z",
      "location_count": 19,
      "location_summary": "Anchorage, Alaska • Los Alamitos, California • Los Angeles, California + 16 more",
      "locations": [
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Los Alamitos",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05048797"
    },
    {
      "nct_id": "NCT04032704",
      "title": "A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Small Cell Lung Cancer",
        "Non-small Cell Lung Cancer, Squamous",
        "Non-small Cell Lung Cancer, Non-squamous",
        "Head and Neck Squamous Cell Carcinoma",
        "Esophageal Squamous Cell Carcinoma",
        "Gastric Adenocarcinoma",
        "Gastroesophageal Junction Adenocarcinoma",
        "Prostate Cancer",
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "ladiratuzumab vedotin",
          "type": "DRUG"
        },
        {
          "name": "pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Seagen Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 205,
      "start_date": "2019-10-09",
      "completion_date": "2023-11-28",
      "has_results": true,
      "last_update_posted_date": "2025-03-10",
      "last_synced_at": "2026-09-24T20:41:10.676Z",
      "location_count": 27,
      "location_summary": "Chandler, Arizona • Los Angeles, California • Santa Rosa, California + 24 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Santa Rosa",
          "state": "California"
        },
        {
          "city": "Norwich",
          "state": "Connecticut"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04032704"
    },
    {
      "nct_id": "NCT02322281",
      "title": "TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Non-small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Rociletinib",
          "type": "DRUG"
        },
        {
          "name": "Pemetrexed or gemcitabine or paclitaxel or docetaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Clovis Oncology, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 149,
      "start_date": "2015-02",
      "completion_date": "2018-03-29",
      "has_results": true,
      "last_update_posted_date": "2019-08-14",
      "last_synced_at": "2026-09-24T20:41:10.676Z",
      "location_count": 31,
      "location_summary": "Bakersfield, California • Duarte, California • Fullerton, California + 27 more",
      "locations": [
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Redondo Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02322281"
    },
    {
      "nct_id": "NCT07287995",
      "title": "A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Locally Advanced or Metastatic Malignant Solid Tumors"
      ],
      "interventions": [
        {
          "name": "ASP2998",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Enfortumab Vedotin",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Astellas Pharma Global Development, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 428,
      "start_date": "2026-02-05",
      "completion_date": "2029-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-09-02",
      "last_synced_at": "2026-09-24T20:41:10.676Z",
      "location_count": 4,
      "location_summary": "Hackensack, New Jersey • New Hyde Park, New York • Nashville, Tennessee + 1 more",
      "locations": [
        {
          "city": "Hackensack",
          "state": "New Jersey"
        },
        {
          "city": "New Hyde Park",
          "state": "New York"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Fairfax",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07287995"
    },
    {
      "nct_id": "NCT03822351",
      "title": "Durvalumab Alone or in Combination With Novel Agents in Subjects With NSCLC",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Stage III Non-small Cell Lung Cancer",
        "Unresectable"
      ],
      "interventions": [
        {
          "name": "Durvalumab + Oleclumab",
          "type": "DRUG"
        },
        {
          "name": "Durvalumab",
          "type": "DRUG"
        },
        {
          "name": "Durvalumab + Monalizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "MedImmune LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 189,
      "start_date": "2018-12-19",
      "completion_date": "2023-07-18",
      "has_results": true,
      "last_update_posted_date": "2024-10-08",
      "last_synced_at": "2026-09-24T20:41:10.676Z",
      "location_count": 28,
      "location_summary": "Anaheim, California • Duarte, California • Sacramento, California + 24 more",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "West Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03822351"
    },
    {
      "nct_id": "NCT03679767",
      "title": "A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Non-small Cell Lung Cancer",
        "Locally Advanced Urothelial Cancer",
        "Metastatic Urothelial Cancer",
        "Unresectable Melanoma",
        "Metastatic Melanoma",
        "Locally Advanced Renal Cell Carcinoma",
        "Metastatic Clear-Cell Renal Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Retifanlimab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Incyte Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 121,
      "start_date": "2019-01-09",
      "completion_date": "2022-06-28",
      "has_results": true,
      "last_update_posted_date": "2023-07-21",
      "last_synced_at": "2026-09-24T20:41:10.676Z",
      "location_count": 18,
      "location_summary": "Fresno, California • San Marcos, California • Santa Rosa, California + 13 more",
      "locations": [
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "San Marcos",
          "state": "California"
        },
        {
          "city": "Santa Rosa",
          "state": "California"
        },
        {
          "city": "Santa Rosa",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03679767"
    }
  ]
}